Companies › Dizal Pharmaceuticals
6 active drug programs in 40 registered trials: 19 Phase 1, 16 Phase 2, 5 Phase 3; Oncology, Hematology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DZD8586 (Birelentinib) Birelentinib; BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Immune Thrombocytopenia (ITP); Healthy; Diffuse Large B-Cell Lymphoma | Nov 2026 |
| Sunvozertinib EGFR Exon20ins inhibitor | EGFR | Phase 3 | Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; NSCLC; Non Small Cell Lung Cancer … | Dec 2026 |
| Golidocitinib Tyrosine-protein kinase JAK1 inhibitor | JAK1 | Phase 3 | Peripheral T-cell Lymphoma; T-cell Lymphomas; Peripheral T Cell Lymphoma; Maintenance Treatment of Peripheral T-cell Lymphoma … | Nov 2027 |
| DZD9008 EGFR inhibitor | EGFR | Phase 2 | Non-small Cell Lung Cancer | – |
| DZD6008 EGFR inhibitor | EGFR | Phase 1 | Non Small Cell Lung Cancer; Nonsmall-cell Lung Cancer; Non-Small Cell Lung Cancer | Jun 2027 |
| GW5282 | – | Phase 1 | Advanced Solid Tumors; T-cell Lymphomas | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05712902 | Sunvozertinib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Oct 2022 |
| NCT06276283 | DZD9008 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT06295432 | DZD9008 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Jun 2026 |
| NCT06295432 | DZD9008 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Jun 2026 |
| NCT07888569 | DZD8586 (Birelentinib) | Phase 1 | Healthy | Other | Nov 2026 |
| NCT06733051 | Golidocitinib | Phase 2 | Natural Killer T-cell Lymphoma | Oncology | Dec 2026 |
| NCT06855823 | Golidocitinib | Phase 1 | Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | Oncology | Dec 2026 |
| NCT03974022 | Sunvozertinib | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06864624 | Sunvozertinib | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT07369739 | Golidocitinib | Phase 2 | Lymphohistiocytosis | Hematology | Jan 2027 |
| NCT07117890 | Sunvozertinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT06969612 | Golidocitinib | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Oncology | May 2027 |
| NCT06966154 | Golidocitinib | Phase 1 | Natural Killer/T-cell Lymphoma | Oncology | May 2027 |
| NCT07070440 | DZD6008 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT07339345 | Golidocitinib | Phase 2 | Lymphohistiocytosis, Hemophagocytic | Hematology | Jun 2027 |
| NCT06630091 | Golidocitinib | Phase 2 | Peripheral T Cell Lymphoma | Oncology | Jul 2027 |
| NCT07294365 | DZD8586 (Birelentinib) | Phase 2 | Immune Thrombocytopenia (ITP) | Hematology | Jul 2027 |
| NCT07093710 | Golidocitinib | Phase 1 | Peripheral T Cell Lymphoma | Oncology | Aug 2027 |
| NCT06739265 | Golidocitinib | Phase 1 | Peripheral T-cell Lymphoma | Oncology | Sep 2027 |
| NCT06539182 | DZD8586 (Birelentinib) | Phase 2 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Oncology | Sep 2027 |
| NCT06905197 | DZD6008 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Sep 2027 |
| NCT06813365 | DZD6008 | Phase 1 | Nonsmall-cell Lung Cancer | Oncology | Oct 2027 |
| NCT05668988 | Sunvozertinib | Phase 3 | Non-small Cell Lung Cancer | Oncology | Oct 2027 |
| NCT06563999 | Sunvozertinib | Phase 2 | Lung Cancer Stage III | Oncology | Nov 2027 |
| NCT07234162 | Golidocitinib | Phase 3 | Peripheral T-cell Lymphoma | Oncology | Nov 2027 |
| NCT06195189 | Sunvozertinib | Phase 1 | Non Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT07525466 | Golidocitinib | Phase 1 | Extranodal NK T Cell Lymphoma | Oncology | Mar 2028 |
| NCT07079475 | DZD6008 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Jun 2028 |
| NCT07079475 | Sunvozertinib | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Jun 2028 |
| NCT07414758 | Golidocitinib | Phase 3 | Peripheral T Cell Lymphoma | Oncology | Sep 2028 |
| NCT07328217 | GW5282 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2028 |
| NCT07300514 | Golidocitinib | Phase 3 | Maintenance Treatment of Peripheral T-cell Lymphoma | Oncology | Dec 2028 |
| NCT07754890 | Golidocitinib | Phase 1 | Cutaneous T-cell Lymphoma (CTCL) | Oncology | Dec 2028 |
| NCT07139873 | DZD8586 (Birelentinib) | Phase 3 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Oncology | Jan 2029 |
| NCT07380984 | Golidocitinib | Phase 2 | Natural Killer/T-cell Lymphoma | Oncology | Feb 2029 |
| NCT07496229 | Golidocitinib | Phase 1 | T-cell Lymphomas | Oncology | Sep 2029 |
| NCT07496229 | GW5282 | Phase 1 | T-cell Lymphomas | Oncology | Sep 2029 |
| NCT07154264 | DZD8586 (Birelentinib) | Phase 2 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Oncology | Dec 2029 |
| NCT07274761 | Sunvozertinib | Phase 2 | Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer | Oncology | May 2030 |
| NCT07059650 | DZD8586 (Birelentinib) | Phase 1 | Diffuse Large B-Cell Lymphoma | Oncology | Oct 2030 |
Jiangsu Alphamab Biopharmaceuticals Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical BeBetter Med TransThera Sciences (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.